Vitiligo Market

 Market Overview:

The 7 major vitiligo markets reached a value of US$ 307.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 439.1 Million by 2034, exhibiting a growth rate (CAGR) of 3.3% during 2024-2034.

The vitiligo market has been comprehensively analyzed in IMARC's new report titled "Vitiligo Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Vitiligo refers to a long-term autoimmune condition that causes the skin to lose pigmentation or color in patches. This results when melanocytes, the pigment-producing skin cells, are attacked and destroyed by the body's defense system, leaving the skin milky white. The disease can occur anywhere in the body, but it usually starts on the hands, forearms, face, and feet. Depending on the spread and appearance of skin spots, the condition is majorly classified into nonsegmental, segmental, and mixed vitiligo. Individuals suffering from this ailment may experience loss of skin color, altered color in the retina, premature hair whitening, etc. In addition to the physical symptoms, vitiligo can also have a significant psychological impact, causing embarrassment, anxiety, and low self-esteem. Diagnosing this illness is typically based on the patient's medical history and examination of indications. A healthcare professional may use a Wood's lamp, which emits ultraviolet light, to help distinguish between vitiligo and other skin conditions. Additionally, blood tests may be ordered to check for underlying autoimmune disorders that may be associated with the ailment.

The increasing incidence of autoimmune diseases, including Hashimoto's thyroiditis, scleroderma, psoriasis, etc., and the growing cases of nervous system dysfunction are primarily driving the vitiligo market. Furthermore, the rising prevalence of various associated risk factors, such as severe sunburn, stress, skin trauma, genetic predisposition, etc., is also propelling the market growth. In addition to this, the escalating utilization of several medications, including topical corticosteroids and calcineurin inhibitors, which can decrease inflammation and the spread of pigmentation loss, is creating a positive outlook for the market. Moreover, the inflating usage of light therapy for patients that works by stimulating specific growth factors to restore the natural skin color is also bolstering the vitiligo market. Apart from this, the emerging popularity of camouflaging cosmetics, tanning products, and skin dye, since they can aid in covering the appearance of redness, depigmentation, and hyperpigmentation related to the ailment, is acting as another significant growth-inducing factor. Additionally, the widespread adoption of Janus kinase inhibitors, which calm down an overactive immune response and help to repigment the skin, is expected to drive the vitiligo market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the vitiligo market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for vitiligo and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vitiligo market in any manner.

Recent Developments:

• In October 2023, CLINUVEL announced that it had administered SCENESSE (afamelanotide 16mg) to the first vitiligo patient in CUV105, a company-sponsored Phase III research. This trial will enroll 200 vitiligo patients with darker skin types (Fitzpatrick Types IV-VI) to compare the efficacy of SCENESSE in combination with narrowband UVB (NB-UVB) light therapy vs. NB-UVB alone.
• In October 2023, AbbVie reported that its Phase 2b study of upadacitinib (RINVOQ) in people with non-segmental vitiligo met the primary goal of percent change from base in the Facial Vitiligo Area Scoring Index (F-VASI) with the 11 mg and 22 mg dosages at week 24 compared to placebo. For all upadacitinib doses, the percentage decrease from baseline in F-VASI at week 52 was larger than that at week 24. There were no new safety signals discovered that went beyond upadacitinib's known safety profile. Based on these findings, AbbVie is moving its upadacitinib trial program in vitiligo to Phase 3.
• In June 2023, AVITA Medical, Inc. stated that the United States FDA has approved its application for premarket approval (PMA) of its RECELL System for vitiligo therapy. The first FDA-approved therapeutic device for repigmentation of stable depigmented vitiligo lesions is RECELL, which provides a one-time treatment at the point of care. The technology allows a doctor to prepare and transport autologous skin cells from pigmented skin to stable depigmented patches, providing a safe and effective vitiligo treatment option.
• In May 2023, Incyte released new results from a Phase 2b clinical trial that assessed the safety and efficacy of povorcitinib (INCB54707), an experimental oral JAK1 inhibitor, in adult patients with severe nonsegmental vitiligo. Patients treated with povorcitinib demonstrated improvements in overall body and facial repigmentation; the investigational therapy was well tolerated.

Key Highlights:

• Vitiligo affects 0.1-2% of the global population of all races.
• Vitiligo is generally divided into two clinical forms: generalized vitiligo and segmental vitiligo, which appear with unique clinical features and natural histories.
• The most prevalent form of the disease is generalized vitiligo, which accounts for 72-95% of all cases.
• Segmental vitiligo affects a small number of people and is estimated to be more common in children, accounting for up to 30% of cases.
• The prevalence was much higher in older persons, men, and people with fair skin (types I and II on the Fitzpatrick scale).

Drugs:

Opzelura, a new cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib, is the first and only topical JAK inhibitor licensed for use in the United States, intended for the topical treatment of nonsegmental vitiligo in both adult and pediatric patients 12 years and older.

SCENESSE is being developed as the first systemic (whole-body) treatment for vitiligo. Early clinical trial findings of SCENESSE showed that the drug, when combined with NB-UVB phototherapy, could repigment vitiligo lesions more quickly and efficiently than NB-UVB alone, with the best clinical response observed in people with darker skin types (Fitzpatrick Skin Types IV-VI).

Ritlecitinib is an anti-inflammatory and immunosuppressive medication being investigated for the treatment of vitiligo. Ritlecitinib is a kinase inhibitor, which means it blocks kinases, which are immune system proteins, from functioning normally. This, in turn, suppresses immunological pathways considered to contribute to the development of auto-immune illnesses, leading in symptom improvements, such as repigmentation or slowing disease progression in vitiligo.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the vitiligo market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the vitiligo market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current vitiligo marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the vitiligo market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the vitiligo market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the vitiligo market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of vitiligo across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of vitiligo by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of vitiligo by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of vitiligo by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with vitiligo across the seven major markets?
• What is the size of the vitiligo patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of vitiligo?
• What will be the growth rate of patients across the seven major markets?
   

Vitiligo: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for vitiligo drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vitiligo market?
• What are the key regulatory events related to the vitiligo market?
• What is the structure of clinical trial landscape by status related to the vitiligo market?
• What is the structure of clinical trial landscape by phase related to the vitiligo market?
• What is the structure of clinical trial landscape by route of administration related to the vitiligo market?